NCT02868060View on ClinicalTrials.gov

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG

Romiplostim

Trial Locations (5)

Unknown

Peking Union hospital, Beijing

West China hospital, Chengdu

Chinese academy of medical science hematology hospital, Tianjin

Wuxi People's Hospital, Wuxi

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Kyowa Kirin China Pharmaceutical Co., Ltd.

INDUSTRY

NCT02868060 - Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter